<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35227277</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-2094</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of neuroinflammation</Title><ISOAbbreviation>J Neuroinflammation</ISOAbbreviation></Journal><ArticleTitle>ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression.</ArticleTitle><Pagination><StartPage>58</StartPage><MedlinePgn>58</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">58</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12974-022-02421-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative disease characterised by the loss of upper and lower motor neurons. Increasing evidence indicates that neuroinflammation mediated by microglia contributes to ALS pathogenesis. This microglial activation is evident in post-mortem brain tissues and neuroimaging data from patients with&#xa0;ALS. However, the role of microglia in the pathogenesis and&#xa0;progression of amyotrophic lateral sclerosis&#xa0;remains unclear, partly due to the lack of a model system that is able to faithfully&#xa0;recapitulate the clinical pathology of ALS. To address this shortcoming, we describe an approach that generates monocyte-derived microglia-like cells that are capable of expressing molecular markers, and functional characteristics similar to&#xa0;in vivo&#xa0;human brain microglia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, we have established monocyte-derived microglia-like cells from 30 sporadic patients with ALS, including 15 patients with slow disease progression, 6 with intermediate progression, and 9 with rapid progression, together with 20 non-affected healthy controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We demonstrate that patient monocyte-derived microglia-like cells recapitulate canonical pathological features of ALS including non-phosphorylated and phosphorylated-TDP-43-positive inclusions. Moreover, ALS microglia-like cells showed significantly impaired phagocytosis, altered cytokine profiles, and abnormal morphologies consistent with a neuroinflammatory phenotype. Interestingly, all ALS microglia-like cells showed abnormal phagocytosis consistent with the progression of the disease. In-depth analysis of ALS microglia-like cells from the rapid disease progression cohort revealed significantly altered cell-specific variation in phagocytic function. In addition, DNA damage and NOD-leucine rich repeat and pyrin containing protein 3&#xa0;(NLRP3) inflammasome activity were also elevated in ALS patient monocyte-derived microglia-like cells, indicating a potential new pathway involved in driving disease progression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Taken together,&#xa0;our work demonstrates that&#xa0;the&#xa0;monocyte-derived microglia-like cell model&#xa0;recapitulates disease-specific hallmarks and characteristics&#xa0;that substantiate patient heterogeneity associated with disease subgroups. Thus, monocyte-derived microglia-like cells are highly applicable to monitor disease progression and can be applied as a functional readout in clinical trials for anti-neuroinflammatory agents, providing a basis for personalised treatment for patients with ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quek</LastName><ForeName>Hazel</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. Hazel.quek@qimrberghofer.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cun&#xed;-L&#xf3;pez</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Romal</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colletti</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>ALS Clinical Research Centre and Laboratory of Neurochemistry, Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Notaro</LastName><ForeName>Antonietta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Clinical Research Centre and Laboratory of Neurochemistry, Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Tam Hong</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Christine C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Ingham Institute for Applied Medical Research and School of Medicine, Western Sydney University, Liverpool, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yi Chieh</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Brain Tumour Biology, Danish Cancer Society, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikari</LastName><ForeName>Lotta E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Bella</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>ALS Clinical Research Centre and Laboratory of Neurochemistry, Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Anthony R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0003-1802-9891</Identifier><AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. Tony.White@qimrberghofer.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>APP1125796</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant><Grant><GrantID>APP1095227</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant><Grant><GrantID>APP1118452</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuroinflammation</MedlineTA><NlmUniqueID>101222974</NlmUniqueID><ISSNLinking>1742-2094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">DNA damage</Keyword><Keyword MajorTopicYN="N">Inflammasome</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">TDP-43 inclusions</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>1</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35227277</ArticleId><ArticleId IdType="pmc">PMC8887023</ArticleId><ArticleId IdType="doi">10.1186/s12974-022-02421-1</ArticleId><ArticleId IdType="pii">10.1186/s12974-022-02421-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gros-Louis F, Gaspar C, Rouleau GA. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762(11&#x2013;12):956&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16503123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2008;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66(3):177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, et al. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142(5):1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, et al. Addressing heterogeneity in amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2020;62(2):156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddy SL, et al. The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS) BMC Med. 2021;19(1):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816375</ArticleId><ArticleId IdType="pubmed">33468103</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Zhao W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. Curr Opin Neurol. 2021 doi: 10.1097/WCO.0000000000000983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000983</ArticleId><ArticleId IdType="pubmed">34402459</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143(12):3526&#x2013;3539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26(4):459&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. Front Immunol. 2017;8:1005&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE. 2013;7(12):e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, et al. Integrated magnetic resonance imaging and [11C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. 2018;83(6):1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 2019;29(5):1164&#x2013;1177.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, et al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371375</ArticleId><ArticleId IdType="pubmed">32669313</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(6):e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia AM, et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci Rep. 2017;7(1):10046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55(2):221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol. 1993;50(1):30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, et al. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol. 1989;8(6):289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">2533530</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57(7):1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, et al. Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice. Dis Models Mech. 2019 doi: 10.1242/dmm.041947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.041947</ArticleId><ArticleId IdType="pmc">PMC6906635</ArticleId><ArticleId IdType="pubmed">31597644</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun. 2011;25(5):1025&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, et al. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237(1):147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgomori T, et al. Comparative morphometric analysis of microglia in the spinal cord of SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2016;43(10):1340&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">26946061</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. A Neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4(2):385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Graber DJ, Hickey WF, Harris BT. Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation. 2010;7:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825214</ArticleId><ArticleId IdType="pubmed">20109233</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262:111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol. 2012;123(3):395&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595560</ArticleId><ArticleId IdType="pubmed">22210083</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122(9):3063&#x2013;3087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrot J, Imhof S, Wainger BJ. Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs. Neurobiology Dis. 2020;134:104680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7002167</ArticleId><ArticleId IdType="pubmed">31759135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgidani M, et al. Direct induction of ramified microglia-like cells from human monocytes: Dynamic microglial dysfunction in Nasu-Hakola disease. Sci Rep. 2014;4(1):4957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019954</ArticleId><ArticleId IdType="pubmed">24825127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellgren CM, et al. Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors. Mol Psychiatry. 2017;22(2):170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5285468</ArticleId><ArticleId IdType="pubmed">27956744</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupton MK, et al. A prospective cohort study of prodromal Alzheimer&#x2019;s disease: prospective imaging study of ageing: genes, brain and behaviour (PISA) Neuroimage. 2021;29:102527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7750170</ArticleId><ArticleId IdType="pubmed">33341723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, et al. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008;275(1):69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, et al. Validation of induced microglia-like cells (iMG Cells) for future studies of brain diseases. Front Cell Neurosci. 2021 doi: 10.3389/fncel.2021.629279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.629279</ArticleId><ArticleId IdType="pmc">PMC8063054</ArticleId><ArticleId IdType="pubmed">33897370</ArticleId></ArticleIdList></Reference><Reference><Citation>Melief J, et al. Characterizing primary human microglia: a comparative study with myeloid subsets and culture models. Glia. 2016;64(11):1857&#x2013;1868.</Citation><ArticleIdList><ArticleId IdType="pubmed">27442614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha NP, et al. Microglia activation in basal ganglia is a late event in huntington disease pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2021 doi: 10.1212/NXI.0000000000000984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000984</ArticleId><ArticleId IdType="pmc">PMC8017723</ArticleId><ArticleId IdType="pubmed">33795375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan SD, et al. Umbilical cord blood-derived microglia-like cells to model COVID-19 exposure. Transl Psychiatry. 2021;11(1):179&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976669</ArticleId><ArticleId IdType="pubmed">33741894</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med. 2010;8(1):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841589</ArticleId><ArticleId IdType="pubmed">20078880</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikari LE, et al. Altered brain endothelial cell phenotype from a familial alzheimer mutation and its potential implications for amyloid clearance and drug delivery. Stem Cell Reports. 2020;14(5):924&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220857</ArticleId><ArticleId IdType="pubmed">32275861</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek H, et al. A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype. Hum Mol Genet. 2017;26(1):109&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">28007901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224(3):213&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Young K, Morrison H. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using imageJ. J Vis Exp. 2018 doi: 10.3791/57648.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/57648</ArticleId><ArticleId IdType="pmc">PMC6103256</ArticleId><ArticleId IdType="pubmed">29939190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley JB, Paschal BM. Fluorescence-based quantification of nucleocytoplasmic transport. Methods. 2019;157:106&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041306</ArticleId><ArticleId IdType="pubmed">30419335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan KJ, et al. A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Sci Transl Med. 2017 doi: 10.1126/scitranslmed.aai7635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7635</ArticleId><ArticleId IdType="pmc">PMC5945290</ArticleId><ArticleId IdType="pubmed">29263232</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-&#x3b2;&#x2013;dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17(1):131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormel PR, et al. A characterization of the molecular phenotype and inflammatory response of schizophrenia patient-derived microglia-like cells. Brain Behav Immunity. 2020 doi: 10.1016/j.bbi.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.08.012</ArticleId><ArticleId IdType="pubmed">32798663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zusso M, et al. Regulation of postnatal forebrain amoeboid microglial cell proliferation and development by the transcription factor Runx1. J Neurosci. 2012;32(33):11285&#x2013;11298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621177</ArticleId><ArticleId IdType="pubmed">22895712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16(3):273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356(6344):eaal3222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2021;92(1):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci. 2016;113(12):E1738&#x2013;E1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Svahn AJ, et al. Nucleo-cytoplasmic transport of TDP-43 studied in real time: impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons. Acta Neuropathol. 2018;136(3):445&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096729</ArticleId><ArticleId IdType="pubmed">29943193</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128(3):423&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P, et al. In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis. 2016;96:236&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5113659</ArticleId><ArticleId IdType="pubmed">27590623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008;116(2):193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64(1):60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A, et al. Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations. Mol Neurodegener. 2020;15(1):51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488163</ArticleId><ArticleId IdType="pubmed">32907630</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer BC, et al. Clustered DNA damage induces pan-nuclear H2AX phosphorylation mediated by ATM and DNa PK. Nucleic Acids Res. 2013;41:6109&#x2013;6118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3695524</ArticleId><ArticleId IdType="pubmed">23620287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. TDP-43 activates microglia through NF-&#x3ba;B and NLRP3 inflammasome. Exp Neurol. 2015;273:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Deora V, et al. The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia. 2020;68(2):407&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">31596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadhim H, et al. In-situ expression of Interleukin-18 and associated mediators in the human brain of sALS patients: Hypothesis for a role for immune-inflammatory mechanisms. Med Hypotheses. 2016;86:14&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26804591</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S, et al. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63(12):2260&#x2013;2273.</Citation><ArticleIdList><ArticleId IdType="pubmed">26200799</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder K, Tschopp J. The Inflammasomes. Cell. 2010;140(6):821&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">20303873</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes-Alnemri T, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14(9):1590&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345951</ArticleId><ArticleId IdType="pubmed">17599095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2006;179(1&#x2013;2):87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857270</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu GN, et al. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem Res. 2008;33(6):1145&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18246426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16(6):771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron. 2017;95(2):297&#x2013;308.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519492</ArticleId><ArticleId IdType="pubmed">28669544</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, et al. ALS-derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP-43 aggregation and a higher susceptibility to DNA damage. J Neurol. 2020;267(5):1291&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">31938860</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, et al. Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDP-43 subcellular distribution. Neuropathol Appl Neurobiol. 2017;43(2):133&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">27178390</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, et al. Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathol. 2011;121(5):611&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">21120508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132(3):391&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2005;159(1&#x2013;2):215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapellos TS, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019 doi: 10.3389/fimmu.2019.02035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02035</ArticleId><ArticleId IdType="pmc">PMC6728754</ArticleId><ArticleId IdType="pubmed">31543877</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill RB, et al. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Communications. 2020 doi: 10.1093/braincomms/fcaa013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa013</ArticleId><ArticleId IdType="pmc">PMC7530830</ArticleId><ArticleId IdType="pubmed">33033799</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, et al. Increased activation ability of monocytes from ALS patients. Exp Neurol. 2020;328:113259.</Citation><ArticleIdList><ArticleId IdType="pubmed">32105709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol. 2017;74(6):677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci. 2019;116(10):4696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: Mechanisms of mitochondriopathy and cell death. J Comp Neurol. 2007;500(1):20&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099894</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C-H, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020 doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubbelaar ML, et al. The kaleidoscope of microglial phenotypes. Front Immunol. 2018;9:1753&#x2013;1753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6079257</ArticleId><ArticleId IdType="pubmed">30108586</ArticleId></ArticleIdList></Reference><Reference><Citation>Carla C-L, et al. 3D models of Alzheimer&#x2019;s disease patient microglia recapitulate disease phenotype and show differential drug responses compared to 2D. Berlin: Nature Portfolio; 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>